Chair, Department of Chemical Physiology, The Scripps Research Institute; Co-director, Center for Physiological Proteomics, The Scripps Research Institute
President & CEO, Indiana Biosciences Research Institute
Director, Life Sciences Institute, University of Michigan
Co-Founder and CEO, Wetpaint
Following a well-attended presentation in May about In-Q-Tel, the private technology acquisition company that serves the U.S. intelligence community, Mintz Levin partner Jonathan Cain will discuss how such investments are structured. Over two-thirds of the companies entering into an In-Q-Tel investment have never sold or licensed technology to the federal government, and for many it is the most significant sale they will make before being acquired. Cain, who has broad experience in all aspects of government procurement law, will explore the risks and potential rewards of entering into such transactions and how to get the most out of an In-Q-Tel investment while protecting the value of the company’s technology. More information and online registration is here.